PD-L1 assessment in tumor tissue has been widely used to identify patients who will benefit from immune-checkpoint inhibition; however, intratumor heterogeneity may cause false negative results [1] and patients with low PD-L1 expression may also take advantage from pembrolizumab [2]. This evidence concerns the gene CD274 and neoplasm.